Your browser is no longer supported. Please, upgrade your browser.
Bicycle Therapeutics plc
Index- P/E- EPS (ttm)-2.65 Insider Own0.20% Shs Outstand21.07M Perf Week3.77%
Market Cap706.51M Forward P/E- EPS next Y-3.38 Insider Trans-74.65% Shs Float2.34M Perf Month4.36%
Income-51.00M PEG- EPS next Q-0.66 Inst Own44.90% Short Float18.88% Perf Quarter15.49%
Sales10.40M P/S67.93 EPS this Y3.90% Inst Trans5.04% Short Ratio2.52 Perf Half Y55.57%
Book/sh4.53 P/B6.50 EPS next Y-15.80% ROA-35.20% Target Price36.75 Perf Year101.44%
Cash/sh5.67 P/C5.19 EPS next 5Y- ROE-57.00% 52W Range12.54 - 33.20 Perf YTD64.07%
Dividend- P/FCF- EPS past 5Y- ROI-46.60% 52W High-11.30% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low134.85% ATR2.50
Employees87 Current Ratio6.70 Sales Q/Q-28.30% Oper. Margin- RSI (14)54.51 Volatility7.99% 9.48%
OptionableNo Debt/Eq0.15 EPS Q/Q-237.50% Profit Margin- Rel Volume0.43 Prev Close29.97
ShortableYes LT Debt/Eq0.15 Earnings- Payout- Avg Volume174.96K Price29.45
Recom1.60 SMA204.62% SMA508.20% SMA20038.47% Volume75,750 Change-1.74%
Oct-12-20Initiated Cantor Fitzgerald Overweight $30
Jun-12-20Initiated Oppenheimer Outperform
Apr-17-20Initiated H.C. Wainwright Buy $25
Nov-14-19Initiated ROTH Capital Buy $17
Sep-11-19Upgrade Goldman Neutral → Buy $14
Jun-17-19Initiated Piper Jaffray Overweight $20
Jun-17-19Initiated Jefferies Buy $22
Jun-17-19Initiated Goldman Neutral $14
Jun-17-19Initiated Canaccord Genuity Buy $22
Apr-10-21 08:30AM  
Apr-09-21 07:32AM  
Mar-30-21 07:00AM  
Mar-18-21 08:34AM  
Mar-11-21 04:05PM  
Mar-07-21 11:11PM  
Jan-26-21 07:20AM  
Jan-14-21 07:00AM  
Jan-06-21 11:58PM  
Dec-09-20 01:32PM  
Nov-24-20 06:59AM  
Nov-20-20 04:05PM  
Nov-12-20 04:01PM  
Nov-09-20 06:59AM  
Nov-08-20 07:17AM  
Nov-05-20 06:59AM  
Oct-21-20 06:59AM  
Oct-14-20 05:08PM  
Oct-01-20 08:06AM  
Sep-19-20 08:03AM  
Sep-18-20 07:30AM  
Sep-14-20 06:59AM  
Sep-10-20 04:05PM  
Sep-03-20 06:59AM  
Sep-02-20 06:59AM  
Sep-01-20 06:59AM  
Aug-06-20 08:03AM  
Aug-05-20 04:05PM  
Jun-24-20 08:37AM  
Jun-23-20 06:59AM  
Jun-22-20 06:59AM  
Jun-13-20 07:56AM  
Jun-12-20 06:46PM  
May-27-20 06:59AM  
May-15-20 06:59AM  
May-13-20 05:09PM  
May-12-20 06:59AM  
May-08-20 09:32AM  
May-07-20 06:59AM  
May-06-20 06:59AM  
May-05-20 06:59AM  
Apr-23-20 06:59AM  
Apr-08-20 07:16AM  
Apr-07-20 06:59AM  
Apr-06-20 06:59AM  
Mar-31-20 07:22AM  
Mar-30-20 11:30AM  
Mar-17-20 06:45AM  
Mar-16-20 08:38AM  
Mar-13-20 12:00PM  
Mar-10-20 06:59AM  
Feb-25-20 06:59AM  
Jan-07-20 07:00AM  
Dec-22-19 06:09PM  
Nov-26-19 07:00AM  
Nov-14-19 07:00AM  
Nov-13-19 07:00AM  
Nov-07-19 07:00AM  
Nov-05-19 08:14AM  
Oct-31-19 07:00AM  
Oct-29-19 07:00AM  
Oct-22-19 03:00AM  
Oct-16-19 04:33PM  
Sep-28-19 06:00AM  
Sep-24-19 07:00AM  
Sep-19-19 09:23AM  
Aug-08-19 07:00AM  
Jul-24-19 08:00AM  
Jul-01-19 07:46AM  
May-23-19 01:09PM  
May-22-19 09:49PM  
May-21-19 04:45PM  
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Legault PierreDirectorApr 08Option Exercise8.7424,838217,08424,838Apr 09 04:36 PM
Legault PierreDirectorApr 08Sale31.7124,838787,5880Apr 09 04:36 PM
Legault PierreDirectorApr 05Option Exercise8.831621,430162Apr 07 07:22 PM
Legault PierreDirectorApr 05Sale31.071625,0330Apr 07 07:22 PM
Legault PierreDirectorMar 31Option Exercise8.7810,00087,80010,000Apr 02 04:44 PM
Keen NicholasChief Scientific OfficerMar 31Sale30.0010,000300,00028,321Apr 02 04:45 PM
Legault PierreDirectorMar 31Sale30.0010,000300,0000Apr 02 04:44 PM
Legault PierreDirectorMar 17Option Exercise8.857,78468,8887,784Mar 19 04:48 PM
Legault PierreDirectorMar 17Sale29.007,784225,7360Mar 19 04:48 PM
Keen NicholasChief Scientific OfficerMar 15Sale28.002176,07638,321Mar 16 07:41 PM
Legault PierreDirectorMar 12Option Exercise8.862,21619,6342,216Mar 16 07:42 PM
Keen NicholasChief Scientific OfficerMar 12Sale28.509,783278,76738,538Mar 16 07:41 PM
Legault PierreDirectorMar 12Sale29.002,21664,2640Mar 16 07:42 PM
Lee KevinChief Executive OfficerFeb 05Sale31.001003,100258,800Feb 09 05:28 PM
Lee KevinChief Executive OfficerJan 20Sale31.881,18537,779258,900Jan 21 04:34 PM
Kalowski LeePresident and CFOJan 19Option Exercise1.5915,00023,85015,000Jan 21 04:29 PM
Lee KevinChief Executive OfficerJan 19Sale29.265,000146,290260,085Jan 21 04:34 PM
Kalowski LeePresident and CFOJan 19Sale30.0015,000450,0000Jan 21 04:29 PM
Lee KevinChief Executive OfficerJan 15Sale27.015,000135,050265,085Jan 15 04:40 PM
Kalowski LeePresident and CFOJan 14Option Exercise1.6010,00016,00010,000Jan 15 04:44 PM
Lee KevinChief Executive OfficerJan 14Sale25.005,000125,000270,085Jan 15 04:40 PM
Kalowski LeePresident and CFOJan 14Sale25.0010,000250,0000Jan 15 04:44 PM
Kalowski LeePresident and CFODec 01Option Exercise1.567,50011,7007,500Dec 03 08:53 PM
Kalowski LeePresident and CFODec 01Sale22.507,500168,7500Dec 03 08:53 PM
Kalowski LeePresident and CFONov 27Option Exercise1.56530827530Nov 30 04:42 PM
Kalowski LeePresident and CFONov 27Sale20.0053010,6000Nov 30 04:42 PM
Kalowski LeePresident and CFONov 25Option Exercise1.569,78115,2589,781Nov 25 08:31 PM
Kalowski LeePresident and CFONov 25Sale20.079,781196,3050Nov 25 08:31 PM
Kalowski LeePresident and CFONov 23Option Exercise1.5617,18926,81517,189Nov 25 08:31 PM
Kalowski LeePresident and CFONov 23Sale19.8317,189340,8050Nov 25 08:31 PM
GLAXOSMITHKLINE PLC10% OwnerJul 15Sale19.403,14761,0451,910,531Sep 18 12:04 PM
GLAXOSMITHKLINE PLC10% OwnerJul 14Sale19.271,59730,7811,913,678Sep 18 12:04 PM